Marina Sharifi is an Oncology physician affiliated with University of Wisconsin System. OpenAlex indexes 149 publications with 1,964 citations (h-index 16); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Uw Hospitals And Clinics
600 Highland Ave
Madison, WI 537920001
Telephone
608-266-6400Provider last certified this registry record 7 Jun 2022.
Clinical trials
- Biomarkers to Detect Endocrine Therapy Resistance
Sponsor: University of Wisconsin, Madison
- Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.5%Aromatase Inhibitor50%Anastrozole75%Letrozole25%Part D<11 patientsEstrogen Agonist/Antagonist6.5%Tamoxifen Citrate100%Part D<11 patientsMetabolism & gastrointestinal
18.6%Serotonin-3 Receptor Antagonist7.6%Ondansetron Hcl100%Part D≥18 patientsH2 blocker4.5%Famotidine100%Part D<11 patients+ 2 more classes in this area
Nervous system
14.4%Phenothiazine5.6%Prochlorperazine Maleate100%Part D≥13 patientsGabapentinoids5.1%Gabapentin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Core B: Bioinformatics and Functional Genomics Core
University of Wisconsin-Madison
FY2026$311,949P01CA298991
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance
Molecular Cancer Research
2026 - Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Amish Raval, MD
University of Wisconsin System
David Bluemke, MD
University of Wisconsin System
David Andes, MD
University of Wisconsin System
Cynthia Carlsson, MD
University of Wisconsin System
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”